These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22656724)

  • 1. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Mauro Gacci, Giovanni Corona, Arcangelo Sebastianelli, et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. Eur Urol 2016;70:788-96.
    Kim JH
    Eur Urol; 2017 Apr; 71(4):e117-e118. PubMed ID: 27815087
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
    Sarma AV; Wei JT
    N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of benign prostatic hyperplasia.
    Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
    Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
    Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
    Sun Y; Peng B; Lei GL; Wei Q; Yang L
    Minerva Urol Nefrol; 2020 Feb; 72(1):13-21. PubMed ID: 31241273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical therapy of male lower urinary tract symptoms].
    Gratzke C; Stief CG
    Urologe A; 2013 Feb; 52(2):184-5. PubMed ID: 23370400
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
    Jin Z; Xin ZC
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):632-5. PubMed ID: 21844982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.
    Serefoglu EC; Mitchell GC; Hellstrom WJ
    Eur Urol; 2012 May; 61(5):e45-6; author reply e47-8. PubMed ID: 22342774
    [No Abstract]   [Full Text] [Related]  

  • 12. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to Jae Heon Kim's Letter to the Editor re: Mauro Gacci, Giovanni Corona, Arcangelo Sebastianelli, et al. Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. Eur Urol 2016;70:788-96.
    Gacci M; Vignozzi L; Corona G; Serni S; Maggi M
    Eur Urol; 2017 Apr; 71(4):e119-e120. PubMed ID: 27816298
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.
    Qiangzhao L; Xiaofeng Z; Fenghai Z; Qiong L; Fa Z; Bohong G; Xinsheng X
    Medicine (Baltimore); 2020 Oct; 99(43):e22834. PubMed ID: 33120811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for non-neurogenic male lower urinary tract symptoms: 1 + 1 does not equal 2.
    Lepor H
    Eur Urol; 2013 Aug; 64(2):244-6; discussion 246-7. PubMed ID: 23473577
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study.
    Gravas S
    Eur Urol; 2015 Aug; 68(2):338-9. PubMed ID: 26149729
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in asian men.
    Kaplan SA
    J Urol; 2014 May; 191(5):1345. PubMed ID: 24745512
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Panagiotis Kallidonis, Constantinos Adamou, Dimitrios Kotsiris, et al. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:537-58.
    Montorsi F; Ventimiglia E; Salonia A
    Eur Urol Focus; 2021 Sep; 7(5):1208. PubMed ID: 32980270
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Alpha-Blockers with or without Phosphodiesterase Type 5 Inhibitor for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
    Kaplan SA
    J Urol; 2020 Feb; 203(2):227-228. PubMed ID: 31710569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.